We used specific agonists, including triptolide (26), ATP (27), 4-chloro-orto-cresol (28) for polycystic kidney disease 2 (PKD2), inositol 1,4,5‐trisphosphate receptors (IP3Rs), and ryanodine receptors, respectively. Here, PKD2 is linked to polycystic kidney disease 2.